Euphrates Vascular
Gregory Stahl serves as the Director of Research and Healthcare Consultant at Euphrates Vascular since January 2022. Gregory also operates as the Principal Owner of Highland Hills Apiary, engaging in the genetic modification of Apis Mellifera and queen grafting. A retired endowed professor from Harvard Medical School, Gregory's tenure from December 1993 to September 2017 included the role of the inaugural Paul Allen Distinguished Professor, where research focused on cardiovascular issues and their relations to various health conditions. Consulting roles have been undertaken with several biotechnology companies, including True North Therapeutics, Catalyst Biosciences, and Alexion Pharmaceuticals, contributing expertise in complement inhibitor programs and the development of biologics. Educational background includes a PhD in Cardiovascular Physiology from Thomas Jefferson University and a BS in Biomedical Sciences from Juniata College.
This person is not in any teams
This person is not in any offices
Euphrates Vascular
Euphrates Vascular develops medical devices that treat vascular occlusions related to vascular disease. Euphrates Vascular's Magnetically-Enhanced Diffusion system uses patented magnet-based technology to transport iron-oxide MED MicroBeads and clot-busting drugs at a much faster rate than otherwise possible, enabling doctors to improve carefor stroke and other diseases.Euphrates Vascular was created through the merger of Pulse Therapeutics and ICHOR Vascular.